PCR Product Portfolio a Key Aspect of Meridian's $23.3M Bioline Buy

Meridian Bioscience's acquisition of Bioline both provides Meridian a foothold in the PCR market and is expected to help drive future diagnostic development at the company.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.